KRINGLE PHARMA INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 13242
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 247
 
  
 
C07K PEPTIDES 2134
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 2165
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 297

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

  • No Recent Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
8927493 Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissueOct 08, 09Jan 06, 15[A61K, A61P, C07K]
8575099 Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereofMar 30, 07Nov 05, 13[A61K, C07K]
8518880 Therapeutic agent for spinal cord injuriesAug 27, 09Aug 27, 13[A61K]
8461112 HGF preparationApr 29, 09Jun 11, 13[A61K]
8383588 Fibrosis inhibitor for implanted organNov 03, 11Feb 26, 13[A61K]
8278270 HGF precursor protein variant and active protein thereofJul 01, 11Oct 02, 12[A61K, C12P, C12N, C07K]
8076289 Fibrosis inhibitor for implanted organJan 28, 10Dec 13, 11[A61K]
8003607 HGF precursor protein variant and active protein thereofMar 30, 07Aug 23, 11[A61K, C12P, C12N, C07K]
7838494 Differentiation- or regeneration-inducing agent for alveoliMar 07, 05Nov 23, 10[A61K, C07K]
7807177 Segment of glycosylation-deficient HGFalpha-chainAug 26, 04Oct 05, 10[A61K, C12N, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2014/0056,910 THERAPEUTIC AGENT FOR CANCER HAVING REDUCED SENSITIVITY TO MOLECULAR TARGET DRUG AND PHARMACEUTICAL COMPOSITION FOR ENHANCING SENSITIVITY TO MOLECULAR TARGET DRUGAbandonedOct 18, 13Feb 27, 14[A61K]
2012/0064,090 THERAPEUTIC AGENT FOR CANCER HAVING REDUCED SENSITIVITY TO MOLECULAR TARGET DRUG AND PHARMACEUTICAL COMPOSITION FOR ENHANCING SENSITIVITY TO MOLECULAR TARGET DRUGAbandonedOct 09, 09Mar 15, 12[A61K, C07D, A61P, C07K]
2010/0322,998 SKIN ULCER PREVENTIVE CURATIVE AGENT CONTAINING HUMAN RECOMBINANT HGFAbandonedJul 23, 10Dec 23, 10[A61K, A61P, A61L]
2010/0279,934 TOPICAL COMPOSITIONS FOR DELIVERY OF PROTEINS AND PEPTIDESAbandonedDec 19, 08Nov 04, 10[A61K, A61P]
7696170 Fibrosis inhibitor for implanted organExpiredSep 09, 05Apr 13, 10[A61K]
2007/0142,279 Agent for promoting induction of vascular differentiation, comprising hepatocyte growth factorAbandonedMar 07, 05Jun 21, 07[A61K]
2007/0021,335 Agent for improving mental disordersAbandonedAug 13, 04Jan 25, 07[A61K]
2006/0293,275 Hgf production accelerator containing heparin-like oligosaccharideAbandonedMar 28, 05Dec 28, 06[A61K]
2006/0228,344 Cell-containing preparationsAbandonedJan 23, 04Oct 12, 06[A61K, C12N]
2006/0199,762 Skin ulcer preventive curative agent containing human recombinant hgfAbandonedAug 27, 04Sep 07, 06[A61K]
2005/0233,299 Method for preserving organs for transplantation with a HGF-containing solutionAbandonedOct 19, 04Oct 20, 05[A01N]
2005/0221,441 Segment of glycosylation-deficient HGF alpha-chainAbandonedJan 25, 05Oct 06, 05[C07H, C12N, C07K]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.